This integrative analysis offers new insights into the immune microenvironment of HER-2-positive BC, suggesting that TILs may serve as a biomarker for combined HER-2 targeted therapy and contribute to optimizing personalized treatment strategies. Here, ERBB2 is linked to breast cancer.